KPV
The C-terminal tripeptide of α-MSH with potent anti-inflammatory action.
How it works
Inhibits NF-κB and MAPK pathways in immune cells, reducing inflammatory cytokine expression independently of melanocortin receptors.
Reported benefits
- Reduction of colonic inflammation in IBD mouse models
- Topical anti-inflammatory effects in dermatology research
- Often paired with BPC 157 for gut-recovery protocols
Dosage & administration
Research range: 250-500 mcg subcutaneously or 500 mcg orally daily.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
KPV reduces colonic inflammation
Gastroenterology · 2008
Oral KPV reduced disease activity in DSS colitis model.
Safety & warnings
- Generally well tolerated in pre-clinical data
- No long-term human studies
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
KP10
Box of 10 · $207
Single vial · $414